BANK VONTOBEL/CALL/GILEAD SCIENCES/76/0.05/20.12.24 | Market Closed - Swiss Exchange 11:20:00 2024-06-20 EDT | ||
| 0.104 CHF | +62.50% |
|
| Current month | +92.59% | ||
| 1 month | +1.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 0.104 | +62.50% |
| 24-06-18 | 0.064 | -3.03% |
| 24-06-17 | 0.066 | +6.45% |
| 24-06-14 | 0.062 | +19.23% |
Delayed Quote Swiss Exchange
Last update June 20, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WGIA3V | |
| ISIN | CH1274773139 |
| Date issued | 2023-07-07 |
| Strike | 76 $ |
| Maturity | 2024-12-20 (183 Days) |
| Parity | 20 : 1 |
| Emission price | 0.46 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.71 CHF |
|---|---|
| Lowest since issue | 0.052 CHF |
| Spread | 0.01 CHF |
| Spread % | 8.77% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.49
USD
Average target price
82.7
USD
Spread / Average Target
+20.74%
- Stock Market
- Warrants
- WGIA3V Warrant
